Alkermes (ALKS) EBITDA Margin (QoQ) (2010 - 2026)
Alkermes (ALKS) EBITDA Margin (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,599.00 |
| Mar 31, 2026 | -2,740.00 |
| Dec 31, 2025 | -749.00 |
| Sep 30, 2025 | -120.00 |
| Jun 30, 2025 | 1,930.00 |
| Mar 31, 2025 | -3,334.00 |
| Dec 31, 2024 | 1,013.00 |
| Sep 30, 2024 | 17.00 |
| Jun 30, 2024 | 1,517.00 |
| Mar 31, 2024 | -211.00 |
| Dec 31, 2023 | -894.00 |
| Sep 30, 2023 | -2,214.00 |
| Jun 30, 2023 | 4,937.00 |
| Mar 31, 2023 | -4,176.00 |
| Dec 31, 2022 | 193,297.00 |
| Sep 30, 2022 | -81,825.00 |
| Jun 30, 2022 | -106,724.00 |
| Mar 31, 2022 | -4,943.00 |
| Dec 31, 2021 | 4,657.00 |
| Sep 30, 2021 | -814.00 |